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ABSTRACT
Background. Prognostic significance of metastatic central
lymph node ratio (CLNR) in papillary thyroid carcinoma
(PTC) remains unknown. Because postsurgical detectable
stimulated thyroglobulin (DsTg) after radioiodine ablation
may imply persistent or recurrent disease, we evaluated the
association between CLNR and rate of DsTg in patients
with PTC who underwent unilateral prophylactic central
neck dissection.
Methods. To be eligible for analysis, the prophylactic
central neck dissection specimen had to contain C3 central
lymph nodes (CLNs) with C1 harboring metastasis. Of 129
specimens, 51 (39.5%) were eligible. CLNR was calculated
as follows: (number of metastatic CLNs/number of CLNs
retrieved) 9 100. They were categorized into group 1 (CLNR
\33.34%) (n = 14), group 2 (CLNR 33.34–66.67%)
(n = 15), and group 3 (CLNR[66.67%) (n = 22). Postab-
lation sTg level was measured 6 months after radioiodine
ablation. A multivariate analysis was conducted to identify
factors for postablation DsTg.
Results. Young age, palpable neck swelling, large tumor
size, advanced tumor, node, metastasis system (TNM)
stage, and large number of metastatic CLNs were signifi-
cantly associated with high CLNR (P \ 0.05). Compared
to groups 1 and 2, group 3 had significantly higher DsTg
rate (P = 0.018). Those who developed subsequent
recurrence had significantly higher DsTg rate than those
who did not (100% vs. 39.1%, P = 0.013). In the
multivariate analysis for postablative DsTg, after adjusting
for age, palpable neck swelling, tumor size, TNM stage,
and number of metastatic CLNs, CLNR was the only
independent factor (odds ratio 1.15, 95% confidence
interval 1.01–1.31, P = 0.036).
Conclusions. A higher CLNR was associated with a
higher rate of postablative DsTg; this may imply higher
future recurrence rate.
Papillary thyroid carcinoma (PTC) is the most common
type of differentiated thyroid carcinoma, and its age-
adjusted incidence has doubled in the last 25 years.1
Despite its relatively good prognosis with a 10-year cancer-
specific survival above 90%, locoregional recurrence is
common.2 With recognition of the concept of stepwise
progression of lymph node metastasis originating from the
central (level VI) to the lateral compartment (levels II–V),
a growing number of surgeons are advocating routine
prophylactic central neck dissection (pCND) at the time of
the total thyroidectomy for PTC.3 Although the role of
pCND remains controversial because there is still no good
evidence to show that it improves long-term outcomes such
as cancer-specific or disease-free survival when compared
to without pCND, the analysis of short-term markers for
recurrence (e.g., postsurgical stimulated thyroglobulin
level, sTg) seems to indicate that pCND may improve
short-term outcomes.4–6
Metastatic lymph node ratio (LNR) (defined as number
of metastatic lymph nodes divided by number of lymph
nodes examined) after prophylactic lymphadenectomy has
been shown to be a promising prognostic variable in a
variety of nonthyroidal primary cancers (e.g., colorectal,
gastric, and pancreatic cancers).7–9 The concept of LNR is
based on the assumption that it indirectly reflects the extent
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or stage of the initial cancer, with a higher ratio implying a
more advanced cancer stage. In addition to the tumor,
node, metastasis system (TNM), LNR has been shown to
be an independent predictor of tumor biology and has been
used to guide adjuvant treatment in select patient
groups.7,8,10 However, the prognostic value of LNR in PTC
has not been as well studied. To our knowledge, two
studies have specifically looked at the prognostic signifi-
cance of LNR in PTC.11,12 Although both studies suggested
that a higher LNR may be associated with poorer survival
outcomes and more advanced disease, they analyzed
patients who underwent prophylactic or therapeutic lym-
phadenectomy. Because pCND has increasingly been
advocated at the time of total thyroidectomy for PTC, our
study aim was to evaluate the impact of metastatic central
lymph node ratio (CLNR) on short-term outcomes (with
sTg used as a surrogate marker) in patients who underwent
unilateral pCND after total thyroidectomy for PTC.13
PATIENTS AND METHODS
Patients
From June 2004 to February 2011, a total of 267 con-
secutive patients with PTC underwent surgery at our
institution. All were managed by the same surgical team. Of
these, 129 (48.3%) underwent a routine unilateral pCND at
the time of the total thyroidectomy. None had evidence of
central lymph node (CLN) metastases preoperatively on
ultrasound (US) or intraoperatively, and those with con-
comitant clinical lymph node metastases (N1b) or distant
metastases (M1) were excluded. To calculate CLNR (%),
the number of metastatic CLNs was divided by the total
number of CLNs retrieved in the excised pCND specimen
and multiplied by 100. During the study period, all resected
specimens were examined by the same group of pathologists
in our institution by using a standardized technique. For this
study, specimens containing \3 CLNs retrieved during
pCND (n = 38) were excluded. This was to avoid falsely
exaggerating the CLNR when only one or two CLNs were
available.11,12 Also because the study aimed to assess the
effect of CLNR rather than the impact of metastatic CLNs on
sTg, specimens containing no metastatic CLN (pN0) were
excluded (n = 40). Therefore, a total of 51 patients were
eligible for analysis. In terms of patient characteristics, most
were women (84.3%) and ethnic Chinese (96.1%). The
median age at operation was 45.0 (range 17.7–71.9) years,
and the median follow-up period was 31.2 (range 7.3–77.1)
months. The median number of metastatic CLNs was 4
(range 1–16) and the median number of CLNs collected was
8 (range 3–26); therefore, the median CLNR was 64.1%
(range 12.5–100.0%). To evaluate the association between
CLNR and other patient characteristics, patients were cate-
gorized into group 1 (CLNR \33.34%) (n = 14), group 2
(CLNR = 33.34–66.67%) (n = 15), and group 3 (CLNR[
66.67%) (n = 22).
Methods
All relevant clinical, laboratory, radiologic, and peri-
operative data were collected prospectively, and follow-up
data were regularly updated in a computerized database.
The present study protocol was approved by the local
institutional review board. Patient clinicopathologic fea-
tures, sTg, and postoperative outcomes were compared
between the three groups.
Management of PTC
Details of surgical treatment, criteria for radioactive
iodine (RAI) ablation, postoperative care, and follow-up
protocol had been described previously.6,14 In brief, total
thyroidectomy was the preferred procedure for all patients
with a preoperative diagnosis of PTC. A similar extent of
unilateral pCND was performed for all patients regardless
of tumor size or extent.6 The pCND consisted of the
removal of all nodes and fibro-fatty tissue extending ver-
tically from the hyoid bone to the thoracic inlet and
laterally from the medial border of common carotid artery
to the midline of the trachea. The ipsilateral recurrent
laryngeal nerve was mobilized and skeletonized along its
entire cervical course. An intraoperative nerve stimulator
was used to confirm its functional integrity.15 Parathyroid
autotransplantation was readily performed. sTg was
defined as a thyroglobulin (Tg) level measured in the
presence of thyroid-stimulating hormone (TSH) at a level
of [30 mIU/L either by 4-week thyroxine withdrawal or
recombinant TSH injections. The preablation sTg levels
were taken approximately 2 months after surgery (at the
time of RAI ablation), while the postablation levels were
taken approximately 9 months after surgery (6–7 months
after RAI ablation or at the time of the whole-body scan).
Tg autoantibodies were measured at the same time. The
decision for RAI ablation was based on the presence of at
least one or more risk factors, such as tumor size [1 cm,
lymph node metastasis, age of [45 years, extrathyroidal
extension, macroscopic postoperative residual disease in
the neck, and distant metastasis; the decision did not
depend on the preablative sTg level. Three gigabecquerels
or 80 mCi of 131I was the standard fixed ablative dose,
while subsequent 131I therapy was performed with
5.5 GBq (or 150 mCi). TSH suppression to below
\0.1 lg/L was recommended for high- and intermediate-
risk patients.
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Postoperative and Follow-up Protocol
Serum calcium and phosphate levels were measured
postoperatively. Calcium with or without vitamin D sup-
plements were prescribed if symptomatic or if calcium was
\1.70 mmol/L. Those who discontinued supplements in
the presence of normocalcemia within 6 months were
considered to have temporary hypoparathyroidism, and
those who needed supplements for [6 months were con-
sidered to have permanent hypoparathyroidism.
Perioperative direct laryngoscopy was performed to assess
vocal cord function. Vocal cord palsy lasting [6 months
was regarded as permanent. All postsurgical patients were
followed up within 4 weeks at a specialized combined
oncology clinic. A follow-up visit was conducted at
3-month intervals in the first 2 years, 6-month intervals in the
next 3 years, and annually thereafter. Clinical examination,
neck US, and nonstimulated Tg level were assessed during
follow-up visits. Locoregional recurrence was defined as
macroscopic disease at clinical examination or US that was
not initially present.
Laboratory Methods
All postoperative sTg levels were measured at the same
laboratory by the same immunometric assay. The assay
used was the Immulite 2000 (Diagnostic Products, Roche,
Los Angeles, CA). This was calibrated against the CRM-
457 standard. A sTg level of [0.5 lg/L was considered
a detectable stimulated thyroglobulin (DsTg). Normal
reference range was \0.5–55 lg/L, and sensitivity was
\0.2 lg/L).
Statistical Analysis
Statistical analysis was performed by the chi-square test
or Fisher’s exact test to compare categorical variables, and
the Mann-Whitney U-test or the Kruskal–Wallis test was
used to compare continuous variables between groups. To
evaluate the correlation between two continuous variables,
the Spearman rank correlation test was performed. Con-
tinuous variables were expressed as medians with ranges.
Variables that were statistically significant in the univari-
ate analysis were entered into multivariate analysis. To
improve clinical utility, before entering into the multi-
variate analysis, some potentially significant continuous
variables such as age and CLNR were converted into
categorical variables. Binary logistic regression analysis
with a variable entrance criterion of 0.05 or less was
conducted to identify factors associated with detect-
able postablative after surgery. All statistical analyses
were performed by SPSS software, version 18.0 (SPSS,
Chicago, IL).
RESULTS
Table 1 shows a comparison of patient clinicopathologic
features, TNM tumor stages, CLNR and metastases, age,
completeness of surgery, invasion, and size (MACIS) score
between groups 1, 2, and 3. The median age at operation
was significantly different between the three groups
(P \ 0.001), with group 3 having the youngest median age.
There was an inverse correlation between age and CLNR
(q = -0.399, P = 0.004). Group 3 was significantly more
likely to present with a palpable swelling than groups 1 and
2 (P = 0.031). There was a direct association between
tumor size and CLNR, with group 3 having the largest
median size relative to groups 1 and 2 (2.8 cm vs. 0.8 cm
and 1.7 cm, respectively, P \ 0.001). Other tumor char-
acteristics like multifocality, capsular invasion,
extrathyroidal extension, and coexistent thyroiditis were
similar between the groups. Regarding TNM staging, group
1 had highest proportion of stage I tumors (P = 0.001) and
the lowest proportion of stage III and IV tumors
(P = 0.001). There were no stage II tumors because
patients aged \45 years with distant metastases and aged
C45 years with no lymph node metastases were already
excluded.
Figure 1 shows the distribution of number of CLNs
collected during pCND in the cohort. The median number
of CLNs retrieved was similar between the three groups
(P = 0.351), but the number of metastatic CLNs excised
was significantly higher in group 3 (P \ 0.001). The
number of CLNs collected was not different between those
aged \45 years and aged C45 years (P = 0.396). The
median number of metastatic CLNs excised in groups 1, 2,
and 3 was 1, 4, and 7, respectively. The MACIS score in
the three groups was not significantly different
(P = 0.068). In terms of postoperative cord palsy, 2
patients (14.3%) in group 1 developed temporary palsy,
and patient 1 (4.5%) in group 3 developed permanent
palsy. The rate of cord palsy was similar between the 3
groups (P = 0.209). For hypoparathyroidism, no patient
developed permanent hypoparathyroidism. The rate of
temporary hypoparathyroidism in groups 1, 2, and 3 were
14.3%, 42.9% and 36.6%, respectively, and were similar
between the three groups (P = 0.227).
Table 2 shows a comparison of postoperative sTg levels,
follow-up period, and recurrence between groups 1, 2, and
3. All patients received RAI ablation 2–3 months after
surgery. In the preablation period, median TSH, sTg, and
the rate of DsTg were similar between the three groups,
while in the postablation period, the median sTg level and
the rate of DsTg were statistically significantly different.
Relative to groups 1 and 2, group 3 had the highest median
postablation sTg level (3.8 lg/L vs. \0.5 and \0.5 lg/L,
respectively, P = 0.031) and rate of DsTg (72.7% vs.
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21.4% and 26.7%, respectively, P = 0.018). Similarly,
although the proportion of preablation DsTg was similar
(P = 0.793), the postablative DsTg was significantly lower
in group 2 than in group 3 (26.7% vs. 72.7%, P = 0.032).
The median follow-up duration and recurrence rate were
similar between the three groups. At the time of analysis,
all patients were alive. In group 1, one patient experienced
bilateral lateral compartment recurrence 32.9 months after
surgery, while in group 2, there was no patient who
developed recurrence. In group 3, four patients developed
ipsilateral lateral compartment. These four recurrences
developed at 13.5, 16.3, 18.5, and 20.9 months, respec-
tively, after surgery. All five of these recurrences had
postablation DsTg 9 months after surgery, and their med-
ian sTg level was 9.7 lg/L (range 2.5–481.0 lg/L). The
patient with the recurrence and a detectable stimulated Tg
of 2.5 had an abnormal US 5 months later. The rate of
DsTg was significantly different between those who
developed recurrence and those who did not (100% vs.
39.1%, P = 0.013). Those with recurrence (n = 5) had
similar number of LNs collected as those without recur-
rence (n = 46) (P = 0.317).
Figure 2 shows the cumulative disease-free survivals for
groups 1, 2, and 3. No differences were observed between
the groups (P = 0.385).
Table 3 shows the results of the multivariable analysis
of clinicopathologic factors for postablation DsTg level
9 months after surgery. Variables that were statistically
significant in the univariate analysis were entered into the
multivariate analysis, except for a palpable neck swelling
and tumor size, because they were interrelated. Therefore,
only one of these two variables was entered into the
TABLE 1 Patient clinicopathologic features, tumor stage, and MACIS score
Characteristic Group 1 (n = 14) Group 2 (n = 15) Group 3 (n = 22) P-value
Age at operation, years 49.0 (47.0–71.9) 45.0 (29.1–70.8) 38.2 (17.7–59.4) \0.001
Sex 0.933
Male 2 (14.3) 2 (13.3) 4 (18.2)
Female 12 (85.7) 13 (86.7) 18 (81.8)
Presented as a palpable neck swelling 8 (57.1) 9 (60.0) 20 (90.9) 0.031
Tumor characteristics
Tumor size, mm 0.8 (0.6–2.2) 1.7 (1.3–3.5) 2.8 (1.0–5.5) \0.001
Multifocality 4 (28.6) 4 (26.7) 6 (27.3) 0.995
Capsular invasion 2 (14.3) 2 (13.3) 6 (27.3) 0.522
Extrathyroidal extension 2 (14.3) 5 (33.3) 6 (27.3) 0.614
Coexisting thyroiditis 4 (28.6) 4 (26.7) 4 (18.2) 0.225
Stage of PTC by TNM 0.001
I 6 (42.9) 2 (13.3) 6 (27.3)
II 0 (0.0) 0 (0.0) 0 (0.0)
III 6 (42.9) 10 (66.7) 9 (40.9)
IV 2 (14.3) 3 (20.0) 7 (31.8)
No. of CLNs retrieved 5 (4–16) 9 (3–26) 9 (3–14) 0.351
No. of metastatic CLNs excised 1 (1–2) 4 (2–16) 7 (3–14) \0.001
Metastatic CLNR, % 20.0 (12.5–25.0) 44.4 (36.4–66.67) 80.0 (70.0–100.0) \0.001
MACIS score 3.84 (3.3–6.3) 4.7 (4.2–7.9) 4.1 (3.2–7.1) 0.068
Continuous variables are expressed as median (range); categorical variables are expressed as n (%)
PTC papillary thyroid carcinoma, TNM 6th edition tumor, node and metastasis staging system, MACIS metastases, age, completeness of surgery,
invasion and size
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FIG. 1 Histogram showing the distribution of total number of CLNs
collected in unilateral pCND
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multivariate analysis at a time. However, regardless of
whether tumor size or a palpable neck swelling was
entered, CLNR (expressed as a continuous variable)
remained the only independent factor for detectable pos-
tablation sTg level (odds ratio 1.15, 95% confidence
interval 1.01–1.31, P = 0.036), after adjusting for TNM
stage, age at operation, and number of metastatic CLNs
excised. When CLNR was entered into the multivariate
analysis as a categorical variable (i.e., \33.34%, 33.34–
66.67%, [66.67%), a CLNR of [66.67% remained the
only independent risk factor for detectable postablation sTg
(b coefficient 3.60, odds ratio 36.64, 95% confidence
interval 1.10–1217.53, P = 0.044).
DISCUSSION
Although LNR carries prognostic significance in several
nonthyroidal cancers, its significance in PTC remains
unclear. Two recent studies reported that a higher LNR in
PTC might be associated with worse outcomes, but they
included patients who underwent prophylactic or thera-
peutic lymphadenectomy. Furthermore, their LNRs were
calculated based on lymph nodes retrieved from both the
TABLE 2 Postoperative sTg levels, follow-up period, and recurrence rate
Characteristic Group 1 (n = 14) Group 2 (n = 15) Group 3 (n = 22) P-value
Preablation perioda
TSH level (mIU/L) 47 (35–99) 43 (30–73) 48 (32–182) 0.679
sTg level (lg/L) 1.5 (\0.5–56.0) 1.5 (\0.5–108.0) 5.4 (\0.5–324.0) 0.543
No. of DsTg 7 (50.0) 10 (66.7) 16 (72.7) 0.505
Postablation periodb
TSH level (mIU/L) 91 (48–146) 52.5 (40–85) 65.5 (30–146) 0.076
sTg level (g/L) \0.5 (\0.5–9.7) \0.5 (\0.5–17.0) 3.8 (\0.5–481.0) 0.031
No. of DsTg 3 (21.4) 4 (26.7) 16 (72.7) 0.018
Follow-up period, mo 22.7 (6.4–65.9) 25.5 (6.1–59.2) 24.6 (6.3–73.7) 0.298
First site of recurrence 0.190
Locoregional 1 (7.1) 0 (0.0) 4 (18.2)
Distant 0 (0.0) 0 (0.0) 0 (0.0)
Continuous variables are expressed as median (range); categorical variables are expressed as n (%)
a Two months after surgery
b Nine months after surgery
TSH thyroid stimulating hormone, sTg stimulated thyroglobulin, DsTg detectable stimulated thyroglobulin (or stimulated thyroglobulin[0.5 lg/L)
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FIG. 2 Cumulative disease-free survival curves of PTC with a
metastatic CLNR of\33.34% (group 1), 33.34–66.67% (group 2), and
[66.67% (group 3) after unilateral pCND
TABLE 3 Multivariable analysis of clinicopathologic risk factors
for postablative DsTg 9 months after surgery
Covariate b
coefficient
Odds ratio
(95% confidence
interval)
P-value
Presented as a palpable swelling
No 1
Yes 1.13 3.10 (0.16–59.89) 0.495
Age at operation 0.101 1.107 (0.90–1.36) 0.338
Metastatic CLNR 0.138 1.15 (1.01–1.31) 0.036
No. of metastatic CLNs 0.672 1.958 (0.85–4.52) 0.115
Stage of PTC by TNM
I 1
II –
III 3.53 34.21 (0.42–2777.84) 0.115
IV 6.43 617.01
(0.31–1235019)
0.098
PTC papillary thyroid carcinoma, TNM 6th edition tumor, node and
metastasis staging system
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central and lateral compartments. Our study aimed spe-
cifically to evaluate the significance of CLNR because
pCND has been increasingly advocated in PTC.6,13 How-
ever, because PTC is an indolent tumor with an excellent
prognosis, it is difficult to adequately evaluate the prog-
nostic significance of CLNR unless a large patient
population followed for a long period is available for
analysis. Because postoperative DsTg after RAI is a sur-
rogate for persistent or recurrent disease, our study aimed
to evaluate the association between CLNR and rate of
DsTg in patients who underwent an unilateral
pCND.13,16–18
In terms of the association between CLNR and clini-
copathologic characteristics, our data showed there was a
marked inverse association between age and CLNR with
group 1 having the oldest median age when compared to
groups 2 and 3. However, because this association has not
been previously evaluated, this finding requires further
validation. Nevertheless, some studies found that young
age was an independent risk factor of CLN metastases, and
so this could possibly account for the higher CLNR in this
age group, assuming that the number of CLNs retrieved
was similar across all ages.19 In our analysis, the number of
CLNs retrieved was not different between those aged
\45 years and those aged C45 years (P = 0.396). Similar
to a recent study, our data showed that tumor size was
directly correlated with CLNR, with larger tumors associ-
ated with higher CLNR.12 However, because both age and
tumor size are important variables in the TNM staging
system, it was surprising that groups 2 and 3 still had a far
greater proportion of stage III and IV tumors than group 1.
In terms of outcomes, our data found there was no sta-
tistically significant association between preablative sTg
and CLNR. However, this would be consistent with our
previous analysis because we previously reported that pre-
ablative sTg level was only dependent on pCND and not on
other clinicopathologic variables, and in our cohort, all
patients underwent pCND.6 On the other hand, our data
found an association between postablative sTg and CLNR
as well as postablative DsTg and CLNR. To further validate
this association, a multivariate analysis was performed. In
the multivariate analysis, after adjusting for factors like age,
palpable neck swelling, number of metastatic CLNs, and
TNM stage, CLNR turned out to be the only independent
factor for postablation DsTg. When entered as a categorical
variable, we found that if the CLNR in the excised pCND
specimen was[66.67%, the chance of having postablative
DsTg was 36.64 times higher than if the CLNR was
\33.34%. Because the number of metastatic CLNs was
adjusted, theoretically a pCND specimen containing 1 of 3
metastatic CLNs would have a similar rate of DsTg as a
specimen containing 2 of 6 metastatic CLNs. However, this
needs to be further validated.
Although DsTg does not always imply higher recurrence
and worse prognosis, all 5 patients who developed recur-
rences in our cohort had DsTg with sTg levels ranging 2.5–
481.0 lg/L. Furthermore, the rate of DsTg was signifi-
cantly different between those who subsequently developed
recurrence and those who did not (100% vs. 39.1%,
P = 0.013). On the basis of these, perhaps a higher CLNR
implies a higher chance of residual microscopic disease
which may in turn lead to higher recurrences. In our cohort,
we believe that some of these ‘‘early recurrences’’ may
actually represent persistent microscopic disease that was
too small to be detected by US in early postoperative
period. Because a unilateral pCND was performed, the
likely site for these residual microscopic diseases included
the contralateral central and/or lateral compartments.
However, because we did not perform contralateral pCND
in cases of lateral recurrence, we could not confirm this.
We believe that these findings may have important
implications. First, a high CLNR might be a parameter for
administering a higher RAI ablation dose after pCND, as
this has not been widely adopted in many institutions. Of
note, despite the 3 GBq ablative dose, none of the
remaining 16 patients in group 3 became athyroglobuli-
nemic, and this differed from group 2, where 6 of 10
remaining patients became athyroglobulinemic. Second,
for surgeons who are contemplating prophylactic lateral
neck dissection in PTC, group 3 would be the group that
might benefit most, although this would mean a second
operation. Regarding whether the contralateral central neck
should be explored in this situation, we could not evaluate
this because none of the 5 locoregional recurrences had the
contralateral central neck explored; however, this would be
an interesting aspect to evaluate in future studies.
Despite these findings, it is important to note that lymph
node status probably has little survival significance in PTC
in patients younger than 45. We also acknowledge certain
shortcomings with our study, including the small number
of patients within each group, potential biases in the
selection for pCND, and subtle variation in histopathologic
findings between pathologists. Some clinicians would
argue that a sTg cutoff of 0.5 lg/L would be too low and a
sTg level taken at 9 months after surgery might be too soon
as an outcome measurement. However, a sTg of\0.5 lg/L
at 1 year has been shown to have a [98% likelihood of
identifying patients completely free of disease at follow-up,
and a stimulated Tg level assessed at 1 year after surgery
has been shown to be as good as a level assessed at
2–3 years after surgery.20,21 Therefore, we believe that sTg
of \0.5 lg/L at 9 months after surgery would serve as a
good surrogate for future recurrences. Interestingly, one of
the recurrences did have a low sTg level of 2.5 lg/L, but
this may be explained by the small volume of recurrent
disease, which was only detected by US 5 months later.
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We postulate that perhaps the recurrent disease might have
been present at the time of sTg testing. Therefore, although
sTg might be a good surrogate, it should be interpreted in
the context of normal imaging findings. The clinical
significance of mildly elevated Tg remains unknown, and
some detectable levels may occasionally decrease with
time.13,20,22 Perhaps with a larger-sized cohort, recurrence
might be a better study end point.
In conclusion, young age, a palpable neck swelling,
large tumor size, advanced TNM stage, and large number
of metastatic CLNs were statistically significantly associ-
ated with a high CLNR. CLNR was the only independent
determinant of DsTg 9 months after surgery. A higher
CLNR was associated with a higher rate of postablative
DsTg, and this may imply higher recurrences in the future.
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